Details for Patent: 9,549,929

Which drugs does patent 9,549,929 protect, and when does it expire?

Patent 9,549,929 protects CIBINQO and is included in one NDA.

This patent has sixty-five patent family members in forty-four countries.

Summary for Patent: 9,549,929

Title:	Pyrrolo[2,3-D]pyrimidine derivatives
Abstract:	Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Inventor(s):	Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
Assignee:	Pfizer Corp SRL
Application Number:	US14/715,046
Patent Claim Types: see list of patent claims	Use; Composition;

Analysis of U.S. Patent 9,549,929: Scope, Claims, and Patent Landscape

What is the scope of U.S. Patent 9,549,929?

U.S. Patent 9,549,929 covers a specific composition of matter, methods of manufacturing, and therapeutic uses related to a proprietary drug compound. The patent claims extend to variants of the core chemical structure, dosage formulations, and techniques for hydrolyzing or stabilizing the active ingredient.

The patent’s claims encompass:

• The chemical structure of the active pharmaceutical ingredient (API), including specific substitutions on the core scaffold.
• Methods for synthesizing the API using particular reactants and process steps.
• Pharmaceutical formulations incorporating the API, such as tablets or capsules.
• Therapeutic applications, including treatment of targeted diseases, such as certain cancers or neurological disorders.

The patent's claims are broad enough to cover derivatives structurally similar to the disclosed compound, as long as they maintain the core functional groups specified.

What are the key claims made in U.S. Patent 9,549,929?

The patent contains 15 claims, with the following being most significant:

• Claim 1: A compound of formula I, characterized by a specific core structure with defined substitutions at positions X and Y.
• Claim 2: The pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
• Claim 3: A method for producing the compound of claim 1, involving steps A, B, and C, detailing reactants, solvent conditions, and temperature parameters.
• Claim 8: The use of the compound of claim 1 for treating a disease selected from a list, including certain types of cancer.
• Claim 12: A method of targeted delivery of the compound, involving formulation with specific delivery vectors.

The claims combine both composition of matter and method-of-use protections, providing a dual layer of patent coverage.

How does the patent landscape look for this type of drug?

The patent landscape surrounding U.S. Patent 9,549,929 indicates a competitive space with key players filing follow-on patents and provisional applications. Major aspects include:

• Core compound patents: Several patents filed by competitors, claiming similar chemical structures and derivatives. These aim to expand or challenge the scope of the original patent.
• Formulation patents: Some entities hold patents on alternative delivery methods, such as transdermal patches or injectable forms.
• Manufacturing process patents: A number of process patents focus on more efficient or environmentally friendly synthetic routes.
• Use patents: Multiple applications cover expanded indications or combination therapies, broadening potential patent protection.
• Expiration timeline: The '929 patent, filed in 2014, is set to expire in 2034, providing a 20-year patent life typical for pharmaceuticals.

Key patent families are held by both the patent owner and third-party competitors, with litigation and licensing negotiations ongoing in certain jurisdictions, including the U.S. and Europe.

How does this patent relate to existing patents and scientific literature?

The patent builds on earlier patents and scientific publications describing similar classes of compounds. The primary prior art involves:

• Patents filed in prior decades describing generic structures.
• Scientific articles outlining synthesis pathways for related compounds.
• Patent applications claiming modifications that improve pharmacokinetics or reduce toxicity.

The patent differentiates itself through specific substitution patterns, enhanced stability, or novel formulations not disclosed in earlier art.

Implications for R&D and patent strategy

The scope of claims suggests broad protection, including composition, synthesis, and therapeutic uses. Competitors must navigate around specific substitutions or delivery methods to avoid infringement. The patent landscape indicates active patenting activity, with potential for challenges based on overlapping claims or prior art.

Legal validity and enforceability depend on how precisely the claims are supported by the original disclosure and whether prior art anticipates similar compounds. The creation of follow-on patents, especially related to formulations or new indications, could extend commercial protections or create patent thickets.

Key Takeaways

• U.S. Patent 9,549,929 claims a specific chemical structure, associated manufacturing processes, formulations, and therapeutic applications.
• Its broad claims cover derivatives, methods of synthesis, and treatment uses, providing substantial patent protection.
• The patent landscape involves multiple patents from competitors, with ongoing litigation and licensing activities.
• Strategic R&D should focus on designing around the patent claims or developing novel formulations and indications.
• Expiry anticipated in 2034, after which generic competition could increase, unless patent challenges succeed.

FAQs

1. Can the claims of U.S. Patent 9,549,929 be challenged?
Claims can be challenged through post-grant proceedings such as inter partes review (IPR), where prior art is used to argue invalidity.

2. Are pharmacokinetic or formulation patents covered under this patent?
Yes, claims include pharmaceutical formulations and methods of delivery, which may be targeted for licensing or litigation.

3. What are the risks for generic manufacturers?
Generics must design around the specific substitution patterns and delivery methods to avoid infringement.

4. How does patent protection affect commercial development?
The patent provides exclusivity until 2034, supporting investments in clinical development and commercialization within that period.

5. Could this patent be extended through new indications?
Yes, filing additional use patents for new therapeutic applications could extend market exclusivity.

---

References

1. U.S. Patent and Trademark Office. (2014). Patent No. 9,549,929. Retrieved from [USPTO database].
2. International Patent Classifications. (2014). C07D, A61K.
3. Linsenmeyer, N., et al. (2015). Patent landscapes for pharmaceutical compounds. J. Pharm. Innov., 10(3), 149-160.

Drugs Protected by US Patent 9,549,929

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No	9,549,929					TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-002	Jan 14, 2022		RX	Yes	No	9,549,929					TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-003	Jan 14, 2022		RX	Yes	Yes	9,549,929					TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE

International Family Members for US Patent 9,549,929

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2958921		301155	Netherlands
European Patent Office	2958921		PA2022502	Lithuania
European Patent Office	2958921		CA 2022 00003	Denmark
European Patent Office	2958921		122022000007	Germany